Chesnara to acquire HSBC Life (UK) for £260 million

Chesnara plc has agreed to acquire HSBC Life (UK) Limited for £260 million, a move set to significantly expand its UK footprint by adding approximately £4 billion in assets under administration and 454,000 policies, bringing the combined group's total assets to around £18 billion. The acquisition, partly funded by a £140 million fully underwritten rights issue, is projected to generate over £800 million in incremental lifetime cash flows and support a 6% increase in Chesnara’s FY25/26 dividends. This strategic transaction, expected to complete in early 2026 pending regulatory approvals, is anticipated to enhance Chesnara's free float and potentially lead to its inclusion in the FTSE 250 index.

Analysis

Chesnara plc's agreement to acquire HSBC Life (UK) Limited for £260 million represents a transformative transaction that will materially increase its scale and market presence. The acquisition will add approximately £4 billion in assets, bringing the group's total to around £18 billion, and strategically deepens Chesnara's footprint in the UK life protection and investment bond market. The financing structure is clear, combining a £140 million fully underwritten rights issue, £55 million in cash, and £65 million from a new credit facility. The rights issue is offered at a steep 40% discount, a tactic to ensure full subscription but one that will cause significant dilution for existing shareholders. Critically, management has provided strong forward guidance, projecting over £800 million in incremental lifetime cash flows and linking the acquisition directly to a 6% increase in the FY25 and FY26 dividends. The deal's valuation at 83% of HSBC Life (UK)'s Solvency II Own Funds appears favorable. Furthermore, the resulting increase in Chesnara's free float could position it for inclusion in the FTSE 250 index, potentially increasing liquidity and institutional demand. The primary contingency remains regulatory approval, with completion targeted for early 2026.

Key Decisions for Investors

• Investors should view this acquisition as a significant value-accretive catalyst for Chesnara, given the strong projections for cash flow generation and a direct 6% dividend uplift, while remaining mindful of the dilutive impact of the rights issue.
• The primary risk factor is execution; investors should closely monitor the progress of the rights issue and the regulatory approval process, as the deal's closing date is not expected until early 2026.
• Consider the potential for a stock re-rating upon completion, as the increased scale and free float may lead to Chesnara's inclusion in the FTSE 250 index, which would likely attract new institutional and passive investment flows.